Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Streptococcus pneumoniae remains a leading cause of global morbidity and mortality, particularly among infants and the elderly. The 13-valent pneumococcal conjugate vaccine (PCV13) represents a milestone in clinical immunology. By conjugating capsular polysaccharides from 13 different serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) to a carrier protein (typically CRM197), the vaccine transforms T-cell independent antigens into T-cell dependent ones. This process induces immunological memory and high-affinity antibodies even in children under two years old.
Information Gain: Unlike early 7-valent or 10-valent formulations, the 13-valent variant offers expanded coverage against serotype 19A, which emerged as a major cause of invasive pneumococcal disease (IPD) and antibiotic resistance worldwide following the introduction of PCV7.
The production of PCV13 is one of the most complex processes in the biological industry. Our technical roadmap involves:
Utilizing proprietary reductive amination or cyanylation technologies to ensure precise bonding between polysaccharides and carrier proteins, maintaining antigenicity while ensuring stability.
High-yield fermentation of the non-toxic mutant of diphtheria toxin (CRM197), ensuring 99%+ purity through multi-stage chromatography purification.
Adjuvant optimization using aluminum phosphate to enhance the immune response while ensuring the vaccine remains stable across the cold chain (+2°C to +8°C).
As a leading Chinese supplier, Jiangxi Serum Pharma leverages the nation's "Industry 4.0" infrastructure to provide unprecedented reliability in the global PCV13 market. Our partner facilities utilize fully automated bioreactors and AI-driven quality control systems.
End-to-end digital tracking from raw material sourcing to final packaging, minimizing human error and ensuring 100% batch-to-batch consistency.
Strategically located hubs in China allow for rapid deployment via air-freight with integrated cold-chain monitoring systems, vital for biological products.
Economies of scale and optimized purification cycles allow us to provide high-quality PCV13 at price points that support large-scale public immunization programs in emerging markets.
Procuring PCV13 is not merely a transaction; it is a critical component of national health strategies. We provide comprehensive macro solutions tailored for GAVI-eligible countries, private healthcare groups, and government tenders.
Assisting local health ministries with clinical data registration, dossier submission (CTD format), and navigating regulatory frameworks to accelerate market entry.
All products adhere strictly to WHO-GMP standards, with pharmacopoeia compliance covering USP, BP, and EP. We provide full COA, CPP, and FSC documentation.
Developing flexible financial models for long-term procurement, ensuring sustainable vaccine supplies for national immunization schedules.
While PCV13 is the current gold standard, Serum Pharma is already looking toward the horizon. The next decade will see a shift toward 15-valent and 20-valent vaccines to address "serotype replacement" – where non-vaccine serotypes begin to fill the ecological niche left by those targeted by PCV13.
R&D Focus: Our roadmap includes exploring mRNA-based pneumococcal vaccines and protein-based universal vaccines that could offer protection across all 100+ known serotypes without the complexity of chemical conjugation.
Deep analysis into the surging demand for plant-derived squalene in vaccine adjuvants...
Learn More →Why Dexamethasone remains a critical molecule for inflammation and respiratory health...
Learn More →FDA approves Lilly's oral weight-loss drug, signaling a shift in the metabolic medicine market...
Learn More →
